

Use of plain language summaries by healthcare professionals: an Open Pharma survey

Pippa Hadland^a, Sarah Thomas^b, Géraldine Drevon^c, Sophie Nobes^d, Slávka Baróniková^e, Jo Gordon^d, Tim Koder^d and Vicky Sanders^d ^aEvidence Generation, Publications and Partnerships, Oncology Business Unit, AstraZeneca, Cambridge, UK; ^bIpsen, Wrexham, UK; ^cGSK, Wavre, Belgium; ^dOxford PharmaGenesis, Oxford, UK; ^eAlfasigma S.p.A., Mechelen, Belgium

WHY WAS THIS NEEDED?

- Plain language summaries (PLS) are easy-to-read summaries of scientific research articles.¹
- Few articles are published with easy-to-read PLS.² However, healthcare professionals (HCPs) and other audiences value PLS,^{3–5} and pharmaceutical companies are increasingly writing PLS to accompany their articles.⁶
- While these studies show that HCPs value PLS, little is known about how HCPs use PLS and which platforms they use to find PLS. We developed a survey to find out.

HOW DO HCPs USE PLS?

Most respondents (72%, 133/185) had read or contributed to at least one PLS; 28% (52/185) had not.

Of the 126 HCPs who did read or contribute to PLS (Figure 2), 34% (43/126) were unsure of their institutional positions on sharing PLS with patients, 59% (74/126) were allowed to share PLS with patients and 7% (9/126) were not (data not shown).

Figure 1. HCPs had mostly read or contributed to short, text-based PLS (A), but they considered both short, text-based and infographic PLS to be the most useful PLS formats (B).











Short (250 - 300 words)

Infographic PLS (graphical **Standalone** PLS of

To better understand the research

as my first language is different

Video PLS

Podcast/ audio PLS

80

Proportion of respondents (%)

100

WHAT DID WE DO?

AIMS

We wanted to know:

- how HCPs use text-based PLS, and how often
- how HCPs find text-based PLS
- what, if anything, could be done to improve how HCPs use and find PLS.


METHODS


- The Open Pharma PLS and discoverability working group designed an 18-question global online survey.
- A copy of the survey can be accessed by scanning the QR code at the bottom of this poster.
- The survey was sent by email to 5141 individuals who had previously contributed to articles sponsored by AstraZeneca, GSK or Ipsen.
- Any HCP who had previously been involved with the development of a pharma-sponsored publication was eligible to respond.
- Each participating pharmaceutical company distributed the survey to their contacts.
- The survey was open from 24 April to 17 June 2024.

WHO RESPONDED TO **OUR SURVEY?**

		text-based	I PLS	summary)	publications		
	nich of the above format read or contributed to? ^a		-	52% (69/133)	28% (37/133)	17% (22/133)	16% (21/133)
B.		700/		710/	350/	270/	770/
Question: Which of the above PLS formats do you find useful, or think would be useful? ^a			-	71% (94/133)	25% (33/133)	27% (36/133)	23% (31/133)
	5% of HCPs had never read	d or used a PLS when a	an article		Nost of the 126 HCPs wh erstanding of publication		ised them to gaii
ncluded one. Question: Wh	nen reading articles with a			quick unde		ns.	ised them to gai
ncluded one. Question: Wh				quick unde Question	erstanding of publication	ns.	76%
ncluded one. Question: Wh typically read	nen reading articles with a	PLS, how often do you		quick under Questions To	erstanding of publication How do you typically u o quickly understand an article	ns. se PLS?ª	
Question: Wh typically read Never R	nen reading articles with a and/or use the PLS?ª	PLS, how often do you	J	quick under Questions To keep	erstanding of publication How do you typically u o quickly understand	ns.	76%
And the second s	hen reading articles with a and/or use the PLS? ^a Rarely Sometimes	PLS, how often do you Most of the time	ı Always	quick under Question: To keep To h	How do you typically u How do you typically u o quickly understand an article up to date with topics outside my speciality help interactions with	ns. se PLS? ^a 33% (42/126) 32%	76%
ncluded one. Question: Whatypically read Never R 5% 1	nen reading articles with a and/or use the PLS? ^a Rarely Sometimes 7% 42%	PLS, how often do you Most of the time 31%	Always	quick under Questions To Fookeep	How do you typically u How do you typically u o quickly understand an article up to date with topics outside my speciality help interactions with ents/advocacy groups	ns. se PLS? ^a 33% (42/126) 32% (40/126)	76%
ncluded one. Question: Whatypically read Never R 5% 1	nen reading articles with a and/or use the PLS? ^a Rarely Sometimes 7% 42%	PLS, how often do you Most of the time 31%	Always	quick under Questions To Fookeep	How do you typically u How do you typically u o quickly understand an article up to date with topics outside my speciality help interactions with	ns. se PLS? ^a 33% (42/126) 32%	76%
ncluded one. Question: Whatypically read Never R 5% 1	en reading articles with a and/or use the PLS? ^a Rarely Sometimes 7% 42% (56/133)	PLS, how often do you Most of the time 31% (41/133)	Always	quick under Questions To State	erstanding of publication How do you typically us of quickly understand an article up to date with topics outside my speciality help interactions with ents/advocacy groups e with patients/carers	ns. se PLS?a 33% (42/126) 32% (40/126) 32%	76%

- A total of 188 people responded to our survey. Three (2%) were excluded because they were not HCPs.
- Of the 185 eligible respondents:







did not speak English

as their first language

had more than 20 years' experience in clinical practice









Each circle represents one respondent. ^aThe 133 respondents who had read or contributed to at least one PLS answered this question. HCP, healthcare professional; PLS, plain language summary(ies).

HOW DO HCPs FIND PLS?

Most HCPs would like all phase 3 (73%, 97/133) and real-world evidence (54%, 72/133) articles to include a PLS (data not shown).

Figure 4. Most HCPs found PLS by chance alongside full-text articles, while one-third used PubMed or Internet searches.

Question: How do you typically find/discover PLS?^a

By chance alongside full-text articles		71% (89/126)
Using PubMed searches	36% (45/126)	
Using Internet search engines (e.g. Google)	31% (39/126)	
On social media (e.g. X, Instagram, Facebook)	17% (21/126)	

Figure 5. Most HCPs would like a PLS to be published alongside the abstract of a full-text article.

10%

10%

(12/126)

^aRespondents could select one or more options from a predefined, multiple-choice list. Respondents who


(12/126)

Question: Where would you like to be able to find a PLS?^a

Other

had 'never' read a PLS (5%, 7/133; Figure 2) did not answer this question.

HCP, healthcare professional; PLS, plain language summary(ies).







REFERENCES

1. Rosenberg A et al. Curr Med Res Opin 2021;37:2015–6; **2.** Gattrell W et al. Curr Med Res Opin 2022;38(Suppl 2):41–2; 3. Lobban D et al. Curr Med Res Opin 2022;38(Suppl 1):32–3; 4. Southey L et al. Presented at the 2024 European Meeting of ISMPP, London, UK; 5. Pushparajah D et al. Ther Innov Regul Sci 2018;52:474–81; 6. Ipsen. Available from: www.ipsen.com/ general/our-pledge-summaries-in-plain-language-for-all-journal-publications/ (Accessed 28 August 2024).

DECLARATION OF FUNDING


This work was supported by Open Pharma. Open Pharma is a multi-sponsor collaborative project facilitated by Oxford PharmaGenesis. At the time of this work, Open Pharma received sponsorship funding from Alfasigma S.p.A., Astellas Pharma Inc., AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim International GmbH, Bristol Myers Squibb, Eli Lilly and Company, F. Hoffmann-La Roche AG, Galápagos NV, Gilead Sciences, Inc., GlaxoSmithKline Biologicals SA, Ipsen Biopharm Ltd, Janssen Scientific Affairs, LLC, a Johnson & Johnson Company, Inc, Novartis Pharma AG, Novo Nordisk A/S, Pfizer Inc., Takeda Development Center Americas, Inc., Taylor & Francis (part of Informa PLC) and UCB Biopharma SRL.

ACKNOWLEDGEMENTS

We thank the Open Pharma PLS and discoverability working group for their guidance during survey development and analysis of results. This poster was originally presented at the 2025 European Meeting of the International Society for Medical Publication Professionals (ISMPP), 27–29 January 2025, London, UK.

DISCLOSURES

PH is an employee and shareholder of AstraZeneca. ST is an employee and shareholder of Ipsen. GD (10: 0000-0002-3508-9127) is an employee and shareholder of the GSK group of companies. SN (10: 0009-0000-7816-0862), JG (10: 0000-0002-1461-5714), TK (10: 0000-0001-6152-7365) and VS (0: 0009-0007-0946-6316) are employees of Oxford PharmaGenesis, where TK is also a shareholder. SB (0: 0000-0001-8072-5690) is an employee of Alfasigma S.p.A.





• PLS are a helpful method of communicating scientific research to time-poor HCPs.

• Most HCPs find PLS by chance alongside full-text articles.

HCPs would like to see more biomedical research publications include a short, text-based PLS, and they would like PLS to be published alongside the abstract in the full-text article.

Publishing more PLS and improving how they are found will help broaden the impact of scientific research.



International licence